Literature DB >> 29424584

Recommendations for the Use of White Blood Cell Growth Factors: American Society of Clinical Oncology Clinical Practice Guideline Update.

Thomas J Smith1, Kari Bohlke1, James O Armitage1.   

Abstract

Year:  2015        PMID： 29424584     DOI： 10.1200/JOP.2015.006742

Source DB:  PubMed          Journal:  J Oncol Pract        ISSN： 1554-7477            Impact factor:   3.840


× No keyword cloud information.
  9 in total

1.  Risk assessment of febrile neutropenia and evaluation of G-CSF use in patients with cancer: a real-life study.

Authors:  Elif Aras; Aygin Bayraktar-Ekincioglu; Saadettin Kilickap
Journal:  Support Care Cancer       Date:  2019-05-24       Impact factor: 3.603

2.  The survival impact of palliative chemotherapy dose modifications on metastatic colon cancer.

Authors:  Mohd Naqib Zainal Abidin; Marhanis Salihah Omar; Farida Islahudin; Noraida Mohamed Shah
Journal:  BMC Cancer       Date:  2022-07-04       Impact factor: 4.638

3.  A retrospective analysis of nadir-neutropenia directed pegylated granulocyte-colony stimulating factor on febrile neutropenia rates in (neo)adjuvant breast cancer chemotherapy regimens.

Authors:  Sarah J Zardawi; Ina Nordman; Nicholas Zdenkowski
Journal:  Cancer Rep (Hoboken)       Date:  2020-08-06

4.  Subcutaneous trastuzumab with pertuzumab and docetaxel in HER2-positive metastatic breast cancer: Final analysis of MetaPHER, a phase IIIb single-arm safety study.

Authors:  Sherko Kuemmel; Carlo A Tondini; Jacinta Abraham; Zbigniew Nowecki; Bartosz Itrych; Erika Hitre; Bogusława Karaszewska; Alejandro Juárez-Ramiro; Flavia Morales-Vásquez; Jose Manuel Pérez-García; Servando Cardona-Huerta; Estefania Monturus; Marco Sequi; Eleonora Restuccia; Mark Benyunes; Miguel Martín
Journal:  Breast Cancer Res Treat       Date:  2021-03-21       Impact factor: 4.872

Review 5.  Refining the role of pegfilgrastim (a long-acting G-CSF) for prevention of chemotherapy-induced febrile neutropenia: consensus guidance recommendations.

Authors:  Matti Aapro; Ralph Boccia; Robert Leonard; Carlos Camps; Mario Campone; Sylvain Choquet; Marco Danova; John Glaspy; Iwona Hus; Hartmut Link; Thamer Sliwa; Hans Tesch; Vicente Valero
Journal:  Support Care Cancer       Date:  2017-08-25       Impact factor: 3.603

6.  Medical management of acute radiation syndrome and associated infections in a high-casualty incident.

Authors:  Nicholas Dainiak
Journal:  J Radiat Res       Date:  2018-04-01       Impact factor: 2.724

7.  Docetaxel, cisplatin, and 5-fluorouracil compared with epirubicin, cisplatin, and 5-fluorouracil regimen for advanced gastric cancer: A systematic review and meta-analysis.

Authors:  Bo Li; Lian Chen; Hong-Liang Luo; Feng-Ming Yi; Yi-Ping Wei; Wen-Xiong Zhang
Journal:  World J Clin Cases       Date:  2019-03-06       Impact factor: 1.337

8.  Optimizing Dose-Adjusted EPOCH Chemotherapy with Long-Acting Granulocyte Colony-Stimulating Factor During the COVID-19 Epidemic.

Authors:  Chong Wei; Yan Zhang; Wei Wang; Wei Zhang
Journal:  Cancer Manag Res       Date:  2021-04-13       Impact factor: 3.989

Review 9.  Pegfilgrastim for primary prophylaxis of febrile neutropenia in multiple myeloma.

Authors:  Claudio Cerchione; Davide Nappi; Giovanni Martinelli
Journal:  Support Care Cancer       Date:  2021-05-14       Impact factor: 3.603
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.